Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions.

Mycoplasma hyopneumoniae (M. hyo) and porcine circovirus type 2 (PCV-2) are major and widespread swine pathogens, both implicated in the porcine respiratory disease complex, which can lead to significant economic losses for pig producers. PCV-2d is currently the most prevalent genotype. Vaccination against these two pathogens helps mitigate their impact on pig health and performance. The use of ready-to-mix or ready-to-use (RTU) vaccines targeting PCV-2a or PCV-2a/b and M. hyo is a common practice. This study aimed to evaluate the efficacy of a novel RTU vaccine containing PCV-2d and M. hyo antigens under experimental conditions. Several challenge trials were conducted using PCV-2a, PCV-2b, PCV-2d, and M. hyo to assess the level of protection conferred against different PCV-2 genotypes and M. hyo, as well as to determine the duration of protection. This study demonstrated that the bivalent PCV-2/M. hyo vaccine induces both early and long-lasting protection against infections caused by M. hyo and PCV-2. In addition, cross-protection against the three major PCV-2 genotypes was confirmed.